Objective To explore the effect of polymorphism in codon Ala54Thr of human intestinal fatty acid-binding protein gene (IFABP)
on the
therapeutic efficacy of fenofibrate. Methods Totally 147 patients with
hyperlipidemia72 men mean age:(56.2±8.63)years;75 women mean age:(58.4±9.12)yearswere enrolled. IFABP genotypes were detected by polymerase chain reaction,HhaⅠ digestion,and sequencing. Four weeks before and after treatment,the levels of fasting serum total cholesterol (TC),triglyceride (TG),high density lipoprotein-cholesterol (HDL-C),low density lipoprotein-cholesterol (LDL-C),apolipoprotein AⅠ(apoAⅠ)and apolipoprotein B (apoB) were detected with biochemical techniques. Results The frequency of IFABP genotype was 0.47 for A/A,0.37 for A/T,and 0.16 for T/T,and the allelic frequency was 0.65 for A and 0.35 for T.No significant differente was found in lipid levels in every genotype before treatment (P>0.05). After 4 weeks of treatment,the levels of TC,TG,LDL-C,and apoB significantlydecreased (P<0.01),and the levels of HDH-C and apoAⅠsignificantly increased(P<0.01). The total therapeutic efficacy on A54A and A54T were 97% and 95%,respectively. In the patients with T54T genotype after treatment,no significant difference in lipids levels was found except TG (P<0.05),and the total efficacy was only 38%. The total therapeutic efficacies of fenofibrate on A54A and A54T were higher than those of T54T,and there was significant different between A54A and T54T(P<0.01). Conclusion The polymorphism of human IFABP gene in hyperlipidemia is related with the therapeutic efficacy of fenofibrate,and the T54T IFABP genotype may have strong negative effect on such efficacy.